Egypt registers first-half primary surplus of EGP 3.2 billion    ITFC approves $2.6 billion financing for Egypt    Hitachi to connect Gulf of Suez wind farm with Egypt national power grid    Egypt works on charting cooperation strategies with international institutions for 5 years: Al-Mashat    Maha karara joins AAIB as Head of Corporate Communications, Sustainability    Over 2.4 million newborns examined for hearing impairment: Health Ministry    Netflix releases trailer of Arab adaption of 'Perfect Strangers' film    Balqees to headline concert celebrating launch of streaming giant LIVENow in MENA    Sawsan Badr to be honoured at Aswan Women Film Festival    Al-Sisi follows up on 'Great Transfiguration Project' in St. Catherine    Cairo, London stress need to strengthen cooperation to face climate change    Foreigners account for 22.6% of Egypt's T-bills issuances in 1H 2021: CBE    MP Abdel Hady Al-Qasby calls government to facilitate and support NGOs    Egypt's ambassador to Italy passes away    Egypt confirms readiness to help African countries face terrorism and extremism    An estimated 235 million people needed humanitarian assistance and protection in 2021, an increase of 40% compared to 2020: IOM Egypt    Egypt, DRC discuss water cooperation during WYF    Egypt, DR Congo discuss boosting bilateral cooperation during WYF    Cameroonian police probe assault on three Algerian journalists covering AFCON    Pharaohs start AFCON 2021 campaign with fierce clash against Nigeria    Foreign Ministry opens capacity building course for French-speaking African diplomats    BRICS development bank admits Egypt as new member    Nermien Ismail Schools opens a new campus in O'West    Netherlands Embassy, E7kky Magazine celebrate success of 21 Egyptian women    Women make up 45% of Egyptian Atomic Energy Authority staff    Yas Island hosts travel partners at Formula 1 Etihad Airways Abu Dhabi Grand Prix 2021    Olaf Scholz becomes Germany's new leader, ending Merkel 16-year historic era    Egypt's trade with Nile basin countries climbs 26% y-o-y in 9 months    The unvaccinated prohibited from entry to Egypt state institutions starting December 1    Egypt's iron and steel exports jump 197% in 8 months    Ethiopia halts work at its embassy in Egypt for 'economic reasons'    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Russia says it's in sync with US, China, Pakistan on Taliban    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    Brazil calls up 8 EPL players for World Cup qualifying    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Sisi calls on House, Senate to commence second legislative sessions on 3, 5 October    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    Qa'a play showing at Lycee El Horreya Theatre, Alexandria is a must go    On International Museum Day, Egypt opens two new museums at Cairo Airport    Old Cairo's Al-Fustat will be revamped on Egyptian President's directives    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



US starts clinical trial of potential COVID-19 vaccine
Another Chinese vaccine is scheduled to apply for clinical trial by April-end
Published in Daily News Egypt on 18 - 03 - 2020

While the panic over the novel Coronavirus (COVID-19) is increasing globally, scientists are racing to develop vaccines against COVID-19 to help to contain the outbreak.
Health authorities around the world have confirmed that more than 189,160 people were infected last week.
Meanwhile, scientists in a Seattle research institute have started the first phase of clinical trial of a potential COVID-19 vaccine for human use. The vaccine was developed through a partnership between the US National Institute of Allergy and Infectious Diseases (NIAID) and Moderna, a biotechnology company based in Cambridge, Massachusetts.
For the first clinical trial, the scientists tried the vaccine on four adults out of 45 eventual participants, received their first doses of the experimental vaccine as the first step in a long process to prove the new drug's safety and effectiveness.
According to scientists at the Kaiser Permanente Washington Health Research Institute which hosts the trials, participants will receive various first doses of the vaccine, over the next six weeks, followed by a second dose 28 days later.
Over a 14-month period, scientists will evaluate the effectivity of the vaccine and follow up on its impacts on the participants through visits both in person and over the phone. Depending on the results of the blood samples taken from the participants, researchers will be able to evaluate the body's immune response to the experimental vaccine.
The new vaccine was created just 42 days after the genetic sequence of the virus called "SARS-CoV-2". According to a science report published in Nature this week, SARS-CoV-2 is the seventh virus of the large family of coronaviruses known to infect humans. These viruses have the ability to cause severe disease. Researchers have confirmed that their analyses clearly showed that SARS-CoV-2 is not a laboratory construct or a purposefully manipulated virus.
Moderna's announcement came after about two months since the COVID-19 outbreak has emerged in the Chinese province of Hubei in December 2019. Since then, hundreds of medical experiments and trials were conducted to find out a vaccine for the deadly infectious.
In a statement at the White House on Monday, Dr. Anthony Fauci, director of the US National Institutes of Health, said that the new vaccine "marked just the beginning of a series of studies in people needed to prove whether the shots are safe and could work. Even if the research goes well, a vaccine would not be available for widespread use for 12 to 18 months."
He added that sharing the genetic sequence of the virus by the Chinese scientists 65 days ago, was a record for developing a vaccine to test.
Coronavirus vaccine was a reason for a debate between the United States and Germany, as Washington has attempted to persuade a German firm "CureVac" working on developing a possible vaccine for Covid-19 to move its research work to the US.
The call was rejected by the German side who accused US President Donald Trump of trying to monopolise any new vaccine exclusively, in the US.
Shortly after his return to Berlin from a visit to the US to attend a meeting with Trump and Vice President Mike Pence, who heads the White House coronavirus task force, chief executive of the German firm CureVac, Daniel Menichella, was announced to leave his post which he had held for two years.
The reason behind his sudden departure is not known until now, but media reports linked this step to his visit to Washington as Berlin showed no tolerance with Trump's offer.
In the meantime, Chinese scientists revealed that they are about to develop some vaccines against the novel Coronavirus disease known as COVID-19. According to Chinese officials in media statements on Tuesday, Chinese higher education institutions are expected to enter clinical trials for some of these vaccines as soon as possible.
Lei Chaozi, an official in the Chinese Ministry of Education, said at a press conference in Beijing that the first of these vaccines is based on the flu viral vector, and is currently under animal experimentation for safety and efficacy tests.
The new vaccine is expected and scheduled to apply for the clinical trial by the end of April.
Simultaneously, Australian scientists are also devoting their efforts for studying the new infection, and finally they said they have come to know how the immune system is fighting the Covid-19.
Their research, whose results were published in the Nature Medicine on Tuesday, revealed that people with the virus are recovering in the same way as people with normal flu.
Experts also say that identifying the types of immune cells that appear after infection with the Coronavirus will help to develop a vaccine against it.


Clic here to read the story from its source.